{"pageContent": "More than two decades of studies on hormonal treatment of Prostate Cancer are briefly reviewed. Recent American Society of Clinical Oncology recommendations have pointed the major issues faced in randomized clinical trials and meta-analyses. Androgen ablation remains the mainstay of treatment for advanced stages, while Docetaxel based chemotherapy is becoming the standard in hormonorefractory tumors and targeted therapies are approaching.", "metaData": {"source": "Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic review\nhttps://pubmed.ncbi.nlm.nih.gov/27809594/"}}